Commissioner's National Priority Voucher (CNPV) Pilot Program
The FDA has introduced the Commissioner's National Priority Voucher (CNPV) Pilot Program, which aims to reduce review timelines for drugs and biologics. Under this pilot, review cycles could potentially be shortened from the standard 10–12 months to a duration of 1–2 months.
This program affects manufacturers of drugs and biologics seeking expedited market entry for products designated as national priorities. It impacts regulatory affairs and clinical development teams responsible for submission timelines.
The reduction of review timelines to 1–2 months represents a significant departure from standard and even existing priority review cycles. While the source provides limited detail on eligibility, such an accelerated pace implies that the FDA may require high-quality, mature data packages and potentially increased pre-submission engagement. For sponsors, this could substantially decrease the time to market, though it may also intensify the pressure on internal CMC and QA teams to support rapid post-submission queries.
Regulatory affairs departments should monitor for detailed eligibility criteria and application procedures for the CNPV pilot. Teams should assess whether existing development programs align with national priority designations to potentially leverage the accelerated review timeline.
FDA Commissioner's National Priority Voucher Program. The Commissioner's National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.
Open in openFDA / FDA.gov